Replies to post #7554 on Tenax Therapeutics Inc (TENX)

[zino]

Levosimendin demonstrated statistically significant reductions in two of three secondary endpoints including:
Reduction in low cardiac output syndrome (LCOS)
Reduction in postoperative use of secondary inotropes.

[zino]

Levosimendin Phase3 Results Still Have Value
Levosimendin demonstrated statistically significant reductions in two of three secondary endpoints including:
Reduction in low cardiac output syndrome (LCOS)
Reduction in postoperative use of secondary inotropes.

[blimps]

NO it does not. The FDA rejected all data.